Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$140.93 USD

140.93
827,249

+1.11 (0.79%)

Updated May 20, 2024 04:00 PM ET

After-Market: $141.51 +0.58 (0.41%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (48 out of 248)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Thermo Fisher (TMO) Debuts a New In-Line Metrology Solution

Thermo Fisher's (TMO) new LInspector Edge In-line Mass Profilometer delivers real-time, full-coverage mass loading analysis for battery electrode coating.

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

The strength of the CAG Diagnostics business buoys optimism for IDEXX (IDXX).

Three Reasons to Retain Revvity (RVTY) Stock in Your Portfolio

Revvity's (RVTY) strong product portfolio raises optimism about the stock.

OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp

OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.

Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression

Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.

Tandem Diabetes (TNDM) Gains From Innovation Amid Macro Issues

Tandem Diabetes (TNDM) seeks to grow its business through the acquisition of products or technologies and investments in businesses.

Paragon 28 (FNA) Expands Syndesmotic Repair Line With New Launch

The dynamic functionality of Paragon 28's (FNA) Grappler R3INFORCE System sets it apart from traditional static repair systems, offering a more physiological and anatomical reconstruction option.

Reasons to Add ShockWave Medical (SWAV) to Your Portfolio Now

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Medtronic's (MDT) Newest Evolut TAVR System Gets FDA Approval

Medtronic (MDT) announces the FDA approval of the newest-generation Evolut TAVR system for the treatment of symptomatic severe aortic stenosis.

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Chemed (CHE) Up 2.5% Since Last Earnings Report: Can It Continue?

Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GE HealthCare's (GEHC) PVA to Aid in Capturing Prostate Volume

GE HealthCare (GEHC) announces the launch of Prostate Volume Assist AI-enabled urology software feature, which is likely to boost prostate imaging, capture prostate volume and increase workflow.

3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio

Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.

Here's Why You Should Add Lantheus (LNTH) to Your Portfolio

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

Boston Scientific (BSX) and Scivita Medical Expand Partnership

Boston Scientific (BSX) and Scivita Medical announce an expanded strategic cooperation arrangement.

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

Strength in end markets and strategic collaborations bode well for Thermo Fisher (TMO).

Accuray's (ARAY) CyberKnife Improves Prostate Cancer Treatment

Accuray (ARAY) announces the latest data that supports the use of its CyberKnife System in the treatment of recurrent prostate cancer with stereotactic body radiation therapy.

DexCom (DXCM) Hits 52-Week High: What's Driving the Stock?

Investors are optimistic about DexCom's (DXCM) strong product portfolio.

Stryker's (SYK) Latest Launch to Streamline Procedural Workflows

Stryker's (SYK) latest addition to its Gamma legacy is expected to streamline workflows and enhance usability.

Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay

Myriad Genetics' (MYGN) new patent grant is likely to bolster the ability to deliver a tumor-informed, high-definition MRD assay to the market.

Reasons to Add Cencora (COR) Stock in Your Portfolio Now

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Masimo (MASI) Plans Consumer Business Spin-Off to Drive Growth

Masimo (MASI) is evaluating a proposed separation of its consumer audio and consumer health product business in a bid to improve the profitability of the healthcare business.

Three Reasons to Retain Avantor (AVTR) Stock in Your Portfolio

Avantor's (AVTR) strong product portfolio raises optimism about the stock.

Veeva Systems' (VEEV) Vault EDC Witnesses Increasing Adoption

Veeva Systems' (VEEV) Vault EDC is likely to enable companies to build a modern clinical data foundation.

Reasons to Add Veeva Systems (VEEV) to Your Portfolio Now

Veeva's strong product demand and strategic deals raise optimism about the stock.